{
  "ticker": "PNV",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973992",
  "id": "02973992",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1638",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8hcl91jxpph.pdf",
  "summary": "**Summary of Material Information**  \n\n- **FY25 Cash & Financials**:  \n  - Cash balance (unaudited): **A$33.5m** (up from A$22.0m at 31 March 2025).  \n  - 2H25 operating cash flow: **A$15.7m** (vs. 1H25 outflow of A$12.5m).  \n  - FY25 EBITDA guidance: **A$11.2m\u2013A$12.4m** (vs. prior year A$3.6m).  \n\n- **Capital Expenditure**:  \n  - **A$8.5m** required for new manufacturing facility/R&D centre (FY26 instalments).  \n  - **A$6.9m** to be funded via U.S. debtors\u2019 collection.  \n\n- **Sales Performance**:  \n  - FY25 group sales: **A$118.6m** (+28.9% YoY).  \n    - U.S. sales: **A$88.4m** (+28.7%).  \n    - Rest of World: **A$30.3m** (+29.6%), with standout growth in UK (+51.9%), Canada (+48.5%), and France (+378.8%).  \n  - **NovoSorb MTX sales**: **A$6.7m** (2H25: A$4.6m, up 119% vs. 1H25).  \n\n- **Regulatory & Expansion**:  \n  - **NovoSorb BTM 6mm thickness** received U.S. FDA 510(k) clearance (June 2025).  \n  - First BTM sales in Malaysia, Czech Republic, Malta, Portugal, Peru.  \n  - **Cell therapy collaboration** with Beta Cell Technologies progressing.  \n\n- **Forward Outlook**:  \n  - U.S. sales orders up **58% YoY**; units sold up **43%**.  \n  - Record June 2025 monthly sales: **A$13.7m** (commercial: A$12.8m).  \n  - Webinar: **30 July 2025** (Bell Potter, Chairman David Williams).  \n\n*Omitted: Non-material operational details, webinar link, chairman/CEO quotes, and background company descriptions.*",
  "usage": {
    "prompt_tokens": 1889,
    "completion_tokens": 487,
    "total_tokens": 2376,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T07:03:23.040465"
}